Recently, Eli Lilly announced that its new crown neutralizing antibody bebtelovimab has been granted Emergency Use Authorization (EUA) by the FDA for the treatment of patients with mild to moderate new coronary pneumonia
.
This is the third neutralizing antibody that Eli Lilly has obtained EUA.
The other two are bamlanlvimab (banivirumab) imported from Abcellera and JS016 (etelvizumab) imported from Junshi Bio
.
Bebtelovimab, a broad-spectrum neutralizing antibody introduced by Eli Lilly from Abcellera, has potent neutralizing activity against all currently known mutant strains, including the "Omicron" strain
.
The authorization is based on data from a Phase II clinical BLAZE-4 trial (NCT04634409)
.
This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the safety and efficacy of bebtelovimab alone or in combination in patients with mild to moderate COVID-19
.
The results showed that 175mg bebtelovimab was comparable to bamlanvimab (700mg) + etesevimab (1400mg) + bebtelovimab (175mg) combination therapy in reducing viral titers in patients
.
Not long ago, Eli Lilly had signed an order with the U.
S.
government for 600,000 doses of bebtelovimab neutralizing antibodies, with a total amount of up to $720 million
.
